

ASX Announcement

29 June 2026

BCAL Secures Funding for FY2027

BCAL Diagnostics Limited (ASX: BDX) (BCAL or Company), a healthcare company engaged in early cancer detection, has secured firm commitments for an additional \$4.9 million under its existing \$10 million Convertible Note facility¹. The additional funds will be drawn down as and when required.

In addition, the Company expects to receive the first tranche of its FY2026 Research & Development tax offset claim of \$1.4 million on or around 30 June 2026. The funding represents approximately 56% of BCAL's expected FY26 R&D Tax offset of approximately \$2.5 million. The balance of the tax offset is expected to be received in October 2026.

The funds support BCAL's ongoing investment to develop and commercialise its blood-based early cancer detection portfolio and support the Company's planned activities through FY2027.

BCAL's available early detection portfolio includes BREASTESTplus™, Avantect® Pancreatic, Avantect® Ovarian with BREASTESTplus Version 2, BREASTEST Monitor, and Avantect® multi-cancer test in development.

Anne-Louise Arnett, Chief Executive Officer, said, *"We are delighted with the additional financing commitment for the balance of the Convertible Note facility. In addition, the R&D Tax offset continues to be an important source of non-dilutive funding for BCAL as we advance our early cancer detection portfolio. This funding supports our commercialisation strategy as we focus on making simple blood-based cancer tests more accessible to doctors and patients."*

This announcement has been approved for release by the Board of BCAL.

ENDS**For further information:****Anne-Louise Arnett**

Chief Executive Officer

aarnett@bcaldiagnostics.com**About BCAL Diagnostics**

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTESTplus™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.

¹ see ASX Announcement 20 October 2025